Locust Walk is a global transaction firm serving biopharma and medtech companies in the US, Europe, and Asia.​

Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our Q1 2018 Trends in Medtech Transactions report applies the latest data to analyze current activities in the life science deal landscape. ​
​
In this quarter’s report you can find an overview and analysis of the following across the US, Europe, Japan, and China:​

• Key performance indicators for the medtech market​
• IPO and private financing activity and performance​
• Deal activity for strategic partnerships and M&A

Here’s a summary of key findings:

IPO activities trend towards revenue-generating companies    ​

• Siemens Healthineers ($5.2B) IPO on the Frankfurt Stock Exchange was the largest IPO, a spin-out of Siemens in order to realize the standalone value of its imaging unit​
• Other 2018 IPOs that raised above $25M included Medartis, a provider of medical device and orthopedic trauma ($132.7M) on Swiss stock exchange, Huami ($110M), a fitness tracking wearables manufacturer on NYSE, and Eyenovia, provider of next-gen micro-therapeutics devices for eye diseases ($27.3M) on NASDAQ​

MedTech has experienced strong private fundraising markets and how been further strengthened by Asian investors ​

• Large rounds supporting longer cash runway ​

MedTech M&A activity continues to support industry consolidation​

• Stryker acquisition of Entellus Medical ($664.0M)​
• Boston Scientific acquisition of NxThera ($406.0M)​
• LivaNova acquisition of TandemLife ($250.0M)​
• LivaNova acquisition of ImThera Medical ($225.0M)​
• QIAGEN acquisition of STAT-Dx ($191.0M)​

Increasing FDA MedTech approvals ​

• Allowance of artificial intelligence guided systems ​
• Robotic systems to improve the performance of surgical procedures